Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3024% above fair value
$0.82+0.02 (+2.60%)
Close on Nov 17, 2026Market cap $206.32MP/E –Yield –
Lineage Cell Therapeutics pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Lineage Cell Therapeutics's pe ratio was 3.8× on Oct 31, 2019, against 2.8× a year earlier.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2019 | Oct 31, 2019 | 3.8× | −3.2 |
| 2018 | Jan 31, 2018 | 6.9× | +1.8 |
| 2017 | Dec 29, 2017 | 5.1× | −12.1 |
| 2016 | Dec 30, 2016 | 17.2× | – |
See a number that looks wrong?